These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 19646125)

  • 1. Is it worth the wait?
    Wyllie MG
    BJU Int; 2009 Jul; 104(1):121-2. PubMed ID: 19646125
    [No Abstract]   [Full Text] [Related]  

  • 2. Optimism expressed over prostate drug.
    Jenks S
    J Natl Cancer Inst; 1991 Dec; 83(23):1712-3. PubMed ID: 1722823
    [No Abstract]   [Full Text] [Related]  

  • 3. Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing.
    Ammar H; Malani AK; Gupta C
    BMJ; 2006 Sep; 333(7569):654; author reply 654. PubMed ID: 16990336
    [No Abstract]   [Full Text] [Related]  

  • 4. Dutasteride (Avodart) for benign prostatic hyperplasia.
    Med Lett Drugs Ther; 2002 Dec; 44(1146):109-10. PubMed ID: 12500154
    [No Abstract]   [Full Text] [Related]  

  • 5. Finasteride for benign prostatic hyperplasia.
    Geller DM
    N Engl J Med; 1993 Feb; 328(6):442-3. PubMed ID: 7678437
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)].
    Aliaev IuG; Vinarov AZ; Lokshin KL; Spivak LG
    Urologiia; 2006; (6):83-6. PubMed ID: 17315721
    [No Abstract]   [Full Text] [Related]  

  • 7. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
    Dörsam J; Altwein J
    Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Finasteride for benign prostatic hyperplasia.
    DuBeau CE
    N Engl J Med; 1993 Feb; 328(6):443. PubMed ID: 7678439
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate cancer prevention (AUGUST 2009).
    Keller DL
    Cleve Clin J Med; 2009 Nov; 76(11):630; author reply 630. PubMed ID: 19884290
    [No Abstract]   [Full Text] [Related]  

  • 10. Evolving role of 5-alpha reductase inhibitors in chemoprevention.
    White WM; Kim ED
    Nat Rev Clin Oncol; 2010 Sep; 7(9):487-8. PubMed ID: 20798697
    [No Abstract]   [Full Text] [Related]  

  • 11. Benign prostatic hypertrophy: update on drug therapy.
    Tejani A; Musini V; Perry TL; Mintzes B; Wright JM
    Can Fam Physician; 2006 Sep; 52(9):1075-6, 1077-8. PubMed ID: 17279217
    [No Abstract]   [Full Text] [Related]  

  • 12. RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
    Pitts WR
    J Urol; 2005 Apr; 173(4):1433-4; author reply 1434-5. PubMed ID: 15758829
    [No Abstract]   [Full Text] [Related]  

  • 13. Finasteride.
    Rittmaster RS
    N Engl J Med; 1994 Jan; 330(2):120-5. PubMed ID: 7505051
    [No Abstract]   [Full Text] [Related]  

  • 14. Finasteride for benign prostatic hyperplasia.
    Holdcroft C
    Nurse Pract; 1993 Mar; 18(3):57-8. PubMed ID: 7681553
    [No Abstract]   [Full Text] [Related]  

  • 15. Finasteride to prevent prostate cancer: a new chapter.
    Harv Mens Health Watch; 2009 Jun; 13(11):1-4. PubMed ID: 19579321
    [No Abstract]   [Full Text] [Related]  

  • 16. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years.
    Fenter TC; Davis EA; Shah MB; Lin PJ
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S154-9. PubMed ID: 18611089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride may prevent prostate cancer.
    Thompson CA
    Am J Health Syst Pharm; 2003 Aug; 60(15):1511, 1515. PubMed ID: 12951749
    [No Abstract]   [Full Text] [Related]  

  • 18. Meta-analysis: creating a level playing field for the patient with symptomatic benign prostatic hyperplasia?
    Kirby R
    BJU Int; 2004 Jul; 94(1):2-3. PubMed ID: 15217419
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative analysis of alpha-blocker utilization in combination with 5-alpha reductase inhibitors for enlarged prostate in a managed care setting among Medicare-aged men.
    Issa MM; Lin PJ; Eaddy MT; Shah MB; Davis EA
    Am J Manag Care; 2008 May; 14(5 Suppl 2):S160-6. PubMed ID: 18611090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Orvieto M; Eggener S
    Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.